Patents Assigned to Upjohn
  • Patent number: 6682892
    Abstract: The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvrus in a human host in need of such treatment. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvrus in a human host in need of such treatment.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 27, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred L. Homa, Michael W. Wathen, Todd A. Hopkins, Darrell R. Thomsen
  • Patent number: 6683181
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: January 27, 2004
    Assignee: Pharmacia and Upjohn Comapny
    Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
  • Publication number: 20040010027
    Abstract: The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a hydroxyphenyl-pyrazole derivative represented by formula (I): 1
    Type: Application
    Filed: December 17, 2001
    Publication date: January 15, 2004
    Applicant: PHARMACIA & UPJOHN SPA
    Inventors: Francesco Casuscelli, Roberto D'Alessio, Eduard Felder, Anna Vulpetti
  • Patent number: 6677160
    Abstract: A method for developing a library of compounds, the compound library, a method for identifying ligands for target molecules, and a method for identifying lead chemical templates, which, for example, can be used in drug discovery and design are provided. Certain embodiments of these methods include the use of NMR spectroscopy.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: January 13, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Brian J. Stockman, Kathleen A. Farley, Claudio Dalvit
  • Publication number: 20040006238
    Abstract: The present invention includes a number of novel intermediates such as the (S)secondary alcohol of formula (VIIIA)
    Type: Application
    Filed: June 27, 2003
    Publication date: January 8, 2004
    Applicant: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman
  • Patent number: 6673793
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: January 6, 2004
    Assignee: Pharmacia & Upjohn Co.
    Inventors: Steven Ronald Turner, Suvit Thaisrivongs, Atli Thorarensen
  • Patent number: 6670378
    Abstract: A method of preventing the development of dyskinesias in patients being treated for Parkinson's Disease requires the administration of a pharmacologically effective amount of a substituted phenylazacycloalkane to the patient. The patient is treated for Parkinson's disease by administering at least one dopamine agonist to the patient and by the transplantation of dopamine neurons into the patient's brain.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: December 30, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Kjell A. Svensson
  • Publication number: 20030225058
    Abstract: The invention provides compounds of Formula (I): 1
    Type: Application
    Filed: March 20, 2003
    Publication date: December 4, 2003
    Applicant: Pharmacia & UpJohn Company
    Inventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-Min Fu, Eric Jon Jacobsen, William W. McWhorter, Jeanette K. Morris, Donald Joseph Rogier
  • Patent number: 6656470
    Abstract: The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: December 2, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Terry L. Bowersock, Paul Guimond, Tzu-Chi R. Ju, Argaw Kidane
  • Publication number: 20030220321
    Abstract: Disclosed are compounds of Formula (I): 1
    Type: Application
    Filed: March 20, 2003
    Publication date: November 27, 2003
    Applicant: Pharmacia & UpJohn Company
    Inventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-Min Fu, William W. McWhorter, Jeanette K. Morris, Donald Joseph Rogier, Eric Jon Jacobsen
  • Publication number: 20030219377
    Abstract: The invention provides methods for diagnosing and treating amyloid-related conditions and compounds useful for the same. The invention provides for detecting, imaging, monitoring, diagnosing, and treating conditions characterized by the binding or aggregation of amyloid fibrils. More particularly, the invention relates to using quinolinehydrazone compounds for diagnosing and treating amyloidotic conditions and also as an antioxidant.
    Type: Application
    Filed: April 23, 2003
    Publication date: November 27, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Thomas J. Raub, Geri A. Sawada, Steven P. Tanis, Gregory J. Fici, Allen Edwin Buhl, Donald Bainbridge Carter, Tiziano Bandiera, Jacqueline Lansen, Cesare Pellerano, Luisa Savini
  • Publication number: 20030219820
    Abstract: The present invention provides a method for identifying a test compound that binds to a target species. The method includes: incubating at least one test mixture under isothermal denaturing conditions, each test mixture comprising at least one test compound, and at least one target species, wherein the isothermal denaturing conditions are effective to cause at least a portion of the target species to denature to a measurable extent; detecting a denaturation signal of each target species in the presence of the at least one test compound by a change in the diffusion properties of the target molecule using fluorescence correlation spectroscopy; and comparing the denaturation signal of each target species in the presence of at least one test compound with a denaturation signal of the same target species in the absence of the at least one test compound under the same isothermal denaturing conditions.
    Type: Application
    Filed: May 27, 2003
    Publication date: November 27, 2003
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Dennis E. Epps, Paul K. Tomich, Ferenc J. Kezdy, Charles K. Marschke
  • Patent number: 6653308
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: November 25, 2003
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu Jin, Paul M. Herrinton, Michael A. Mauragis
  • Patent number: 6653307
    Abstract: The present invention provides compounds of formula I which are useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: November 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Mark E. Schnute
  • Patent number: 6653331
    Abstract: The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free —NH— which has been derivatized by the attachment of an electrophile containing a moiety, such as p-CN— or p-NO2-pyridinylsulfonyl groups, or p-NO2- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: November 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Zhiyang Zhao, Alfredo G. Tomasselli, Kenneth A. Koeplinger, Tillie Peterson
  • Patent number: 6653325
    Abstract: A method of preventing the development of dyskinesias in patients being treated for Parkinson's Disease comprising the administrating a pharmacologically effective amount of a substituted phenylazacycloalkane and a dopamine agonist to the patient.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: November 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Kjell A. Svensson
  • Publication number: 20030216330
    Abstract: A method of treating a diabetic foot infection in a mammal includes oral, parenteral, or intravenous administration of a pharmaceutical formulation containing an orally, parenterally, or intravenously-effective amount, respectively of an oxazolidinone.
    Type: Application
    Filed: March 21, 2003
    Publication date: November 20, 2003
    Applicant: PHARMACIA & UPJOHN
    Inventor: Carl Norden
  • Publication number: 20030216572
    Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA)
    Type: Application
    Filed: April 24, 2003
    Publication date: November 20, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman
  • Patent number: 6648851
    Abstract: An applicator for administering a medication to an animal, particularly a mastitis treatment, is made up of an elongated syringe having an integral blunt-tipped cannula provided at one end thereof. The cannula has a first portion for partial insertion of the cannula and a second portion for complete insertion of the cannula. The diameter of the cannula first portion is smaller than the diameter of the cannula second portion and the cannula first and second portions join at an annular shoulder which limits the partial insertion of the cannula.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: November 18, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Thomas Walter Pyret, Fred W. Wall
  • Publication number: 20030207866
    Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
    Type: Application
    Filed: April 15, 2003
    Publication date: November 6, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Stephen J. King